Moderna and Merck’s cancer vaccine breakthrough after a century of failures

• Merck paid $200 million upfront in 2016 and $250 million in 2022 for the partnership, with Wall Street already estimating billions in potential sales for the approved vaccine
• The vaccine (intismeran autogene) targets up to 34 patient-specific cancer mutations using mRNA technology, paired with Keytruda to unleash immune system T-cells against tumors
• The companies are testing whether the approach works in cancers with fewer mutations, including lung, kidney, and pancreatic cancers, while refining the current melanoma vaccine

Summary: Moderna and Merck's Cancer Vaccine Breakthrough

Key Development:

Moderna and Merck have achieved the first successful late-stage trial of a therapeutic cancer vaccine after over a century of failed attempts. The mRNA-based vaccine, intismeran autogene, demonstrated effectiveness in preventing melanoma tumors from recurring or spreading in a trial of more than 1,000 patients with localized melanoma.

Partnership Details:

• Collaboration began in 2016, with Merck paying $200 million upfront
• Additional $250 million payment made in 2022
• Partnership leverages Moderna's mRNA technology with Merck's checkpoint inhibitor Keytruda

How It Works:

The personalized vaccine targets up to 34 patient-specific tumor mutations, training the immune system to attack cancer cells. It's combined with Keytruda, which removes natural immune system barriers. The approach was tested in early-stage melanoma patients post-surgery, providing time to create customized vaccines and allow immune response development.

Market Implications:

• Wall Street projects billions in potential sales
• U.S. approval could come as early as next year
• Critical for Merck as Keytruda faces patent expiration later this decade
• Provides Moderna a lifeline amid declining COVID vaccine demand
• Offers reputational boost for mRNA technology amid recent scrutiny from Health Secretary RFK Jr., who cut $500 million in related projects

Future Plans:

Companies are exploring applications for cancers with fewer mutations, including lung, kidney, and pancreatic cancers. Both firms plan to refine the melanoma vaccine further, with Moderna CEO Stephane Bancel indicating "this is not our last version of intismeran."